Disclaimer: This site aggregates publicly available data from official government sources (FDA, ClinicalTrials.gov, PubMed, SEC EDGAR, NMPA) for general reference only. It does NOT constitute medical advice, diagnosis, treatment recommendations, or investment advice.

Clinical Trial

Efficacy of a New Composition (BU002) for Debridement of Chronic Cutaneous Ulcers

NCT: NCT07607106 · RECRUITING

NCT IDNCT07607106
StatusRECRUITING
Start Date2025-10-01
Completion2026-12

Brief Summary

This study is testing a new liquid treatment for people with long-lasting (chronic) wounds, such as venous leg ulcers or diabetic foot ulcers. These wounds can be difficult to heal because they often contain dead tissue and bacteria. The new product is designed to help clean the wound and remove dead tissue, which may help the wound heal better. It will be compared to a commonly used treatment called Polyhexanide gel. About 80 people aged 60 years or older will take part in this study. Each participant will be randomly assigned (like flipping a coin) to receive either the new treatment or the standard treatment. Neither the participant nor most of the study team will know which treatment is being used during the study to ensure fair results. The study will last 4 weeks. Participants will attend eleven visits at the wound care center. During these visits, trained nurses will clean and treat the wound. The study team will: * Measure the size of the wound * Take small samples from the wound to check for bacteria * Ask questions about pain and general health * Check blood flow in the legs * Perform blood tests at the beginning A specialist doctor will examine the wound at the start and at the end of the study to see how it has improved. Overall, this study aims to find out if the new treatment can help wounds heal better and more quickly than current standard care. Taking part in the study is completely voluntary. Participants can leave the study at any time without affecting their usual medical care. All personal and medical information will be kept confidential.

Frequently Asked Questions

What is Efficacy of a New Composition (BU002) for Debridement of Chronic Cutaneous Ulcers?

Efficacy of a New Composition (BU002) for Debridement of Chronic Cutaneous Ulcers is a clinical trial registered under NCT07607106. Current status: RECRUITING.

What is the status of NCT07607106?

The current status of NCT07607106 (Efficacy of a New Composition (BU002) for Debridement of Chronic Cutaneous Ulcers) is: RECRUITING.

When did Efficacy of a New Composition (BU002) for Debridement of Chronic Cutaneous Ulcers start?

Efficacy of a New Composition (BU002) for Debridement of Chronic Cutaneous Ulcers started on 2025-10-01.

Official Source

View on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov API. For the most current status, refer to the official record.